Group 1

Global Military Drone Market Expected to Reach $18 Billion By 2028 as U.S. Government Plays Crucial Role in Military Drone Industry

Retrieved on: 
星期二, 五月 7, 2024
ARK, Online, UAV, Group 1, Grumman, News, Partnership, AeroVironment, Convention (norm), RCAT, UAS, Defense, LMT, Aircraft, Lockheed Martin, Machine learning, Software, ATAK, NDAA, Special, Telephone, Radio, MANET, Ad hoc, Demonstration, SRR, Sony, Raytheon Technologies, Century, Government, Atmosphere, USD, FPV, PALM, Environment, General Atomics, Northrop Grumman, Technology company, Drone, Growth, Compound annual growth rate

According to a report from MarketsAndMarkets, the military drone market is poised to reach USD 18.2 billion by 2028, with a Compound Annual Growth Rate (CAGR) of 7.0% during the period from 2023 to 2028.

Key Points: 
  • According to a report from MarketsAndMarkets, the military drone market is poised to reach USD 18.2 billion by 2028, with a Compound Annual Growth Rate (CAGR) of 7.0% during the period from 2023 to 2028.
  • The report said: “The global race among nations to invest in drone technology has sparked a competitive environment.
  • This demand for more sophisticated drone capabilities is a key factor stimulating the expansion of the military drone market.
  • The MarketsAndMarkets report continued: “Based on operation mode, The military drone market is divided into remotely piloted, optionally piloted, and fully autonomous categories.

ADAMA Set to Bring Innovation to the European Cereal Herbicide Segment with the Introduction of EDAPTIS®

Retrieved on: 
星期一, 五月 6, 2024
TEL, Rapeseed oil, Thought, Research, Group 1, Farmer, Group 2, Weed control, Agriculture

EDAPTIS® is a ready-to-use solution that provides broad-spectrum control of grassy weeds and improved efficacy in combating resistant populations.

Key Points: 
  • EDAPTIS® is a ready-to-use solution that provides broad-spectrum control of grassy weeds and improved efficacy in combating resistant populations.
  • Leading research in herbicide resistance suggests that stacking modes of action are more effective in mitigating herbicide resistance compared to the conventional practice of rotating herbicide groups.
  • This urgency is compounded by the removal of numerous herbicides, especially in the pre-emergent segment, due to heightened regulatory restrictions," said Darren Palendat, Global Herbicide Product Strategy for ADAMA.
  • EDAPTIS® received registration in Poland and is expected to be registered in multiple European countries including France, Germany, UK, Italy, Spain and others.

EFG Companies Expands Powerhouse Leadership Roster

Retrieved on: 
星期二, 四月 30, 2024
Other Professional Services, Insurance, Other Retail, Automotive, Other Automotive, Professional Services, General Automotive, Retail, Dominion, Motivation, Region, Business development, Group 1, Audi, Digital, Environment, GMC, PVR, EFG, Multimedia, Sales, Strategic planning, Management

EFG Companies, recently named as a USA Today National Standard Top Employer, has added three senior executives with a combined 70+ years of experience in retail automotive sales and finance and insurance (F&I) management.

Key Points: 
  • EFG Companies, recently named as a USA Today National Standard Top Employer, has added three senior executives with a combined 70+ years of experience in retail automotive sales and finance and insurance (F&I) management.
  • (Graphic: Business Wire)
    “While retail automotive remains healthy in relation to profit potential, our clients face a new variety of complex issues that can be distracting and dilutive to the bottom line,” said Jennifer Rappaport, President and CEO of EFG Companies.
  • Prior to joining EFG, Gabe served as Vice President of Sales in the Dealership Division of Vehlo.
  • Prior to joining EFG, Brittany served in finance management and sales management roles for Ken Garff Porsche Audi, Young Automotive Group, and Jerry Seiner Buick GMC.

AV Unveils New AI Capability and Autonomy Kit for Unmanned Systems

Retrieved on: 
星期二, 四月 23, 2024
Software, Defense, Other Defense, Hardware, Artificial Intelligence, Robotics, Data Management, Technology, ARK, AV, Group 1, MANET, Machine learning, ATAK, Ad hoc, AeroVironment, Classification, UAS, Multimedia, Aircraft

AeroVironment (AV) has introduced its Autonomy Retrofit Kit (ARK) and AVACORE software demonstrating the company’s commitment to advancing autonomy and machine learning capabilities to increase effectiveness of autonomous systems and reduce operator burdens.

Key Points: 
  • AeroVironment (AV) has introduced its Autonomy Retrofit Kit (ARK) and AVACORE software demonstrating the company’s commitment to advancing autonomy and machine learning capabilities to increase effectiveness of autonomous systems and reduce operator burdens.
  • ARK and AVACORE bring AV’s accelerated autonomy to fielded assets such as Puma™ 3 AE and Puma™ LE , in addition to future autonomous systems.
  • AVACORE is AV’s autonomy software providing an open framework for unmanned systems.
  • “This results in smarter systems with reduced cognitive load for warfighters.”
    Click here to request additional information on AV’s ARK and AVACORE.

Longhorn Vaccines and Diagnostics Presents at World Vaccine Congress on Advantages of Single Peptide Vaccine for Broad Coverage of Human and Avian Influenza Viruses

Retrieved on: 
星期二, 四月 2, 2024
Health, Infectious Diseases, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Congress, Isotype, Influenza, Group 1, Public, Vaccine, Epitope, ELISA, Mouse, Immunoglobulin G, IND, Immunity, InvivoGen, Poster, Peptide

Results from the poster show that LHNVD-110 generated broadly reactive antibodies to human and highly pathogenic avian influenza viruses while neutralizing seasonal and pandemic influenza strains.

Key Points: 
  • Results from the poster show that LHNVD-110 generated broadly reactive antibodies to human and highly pathogenic avian influenza viruses while neutralizing seasonal and pandemic influenza strains.
  • This data mirrors previous studies with LHNVD-105, a dual peptide vaccines containing the same epitopes.
  • Using a single peptide provides a more cost-effective and easily scalable approach to such a universal influenza vaccine.
  • That is why using peptide-based vaccines with broad strain coverage may offer useful strategies towards preventing influenza, no matter the strain.

NOTICE TO THE ANNUAL GENERAL MEETING IN HEXAGON AB (publ)

Retrieved on: 
星期四, 三月 21, 2024
Transfer, Exercise, Euroclear, Hexagon AB, Bachelor, Chapter Eight, The Annual Report, Remuneration, Audit committee, Microsoft, Annual, Employment, Pension, Committee, Venture round, AGM, Annual general meeting, Section 4, Companies Act, Criterion, Person, Annual report, P.O, Master, University, PwC, Documentation, Group 5, Proxy, Social Security, Acquisition, MD, IBM, Retirement, International business, BankID, Guideline, Conference, Address, Group 1, Mass meeting, Post office box, Nasdaq Stockholm, Chapter Seven, Management

STOCKHOLM, March 21, 2024 /PRNewswire/ -- The Board of Directors has, pursuant to Chapter 7, Section 4 a of the Swedish Companies Act (Sw. aktiebolagslagen) and the company's Articles of Association, decided that shareholders shall be able to exercise their voting rights by postal voting before the General Meeting. Consequently, shareholders may choose to exercise their voting rights at the AGM by attending in person, through a proxy or by postal voting.

Key Points: 
  • Notice of attendance to the Annual General Meeting can be given on Hexagon's website, www.hexagon.com , or by post to: Hexagon AB, "Annual General Meeting", c/o Euroclear Sweden AB, P.O.
  • Completed and signed postal voting forms can be sent by mail to Hexagon AB, "Annual General Meeting", c/o Euroclear Sweden AB, P.O.
  • The Nomination Committee elected in anticipation of the 2024 Annual General Meeting, comprising Mikael Ekdahl (Melker Schörling AB), Jan Dworsky (Swedbank Robur fonder), Brett Watson (Infor) and Daniel Kristiansson (Alecta) has proposed that Ola Rollén be elected Chairman of the 2024 Annual General Meeting.
  • If the Annual General Meeting so resolves, the dividend is expected to be distributed by Euroclear Sweden AB starting on Friday 10 May 2024.

Rebamipide May Combat Low-Grade Inflammation in Post-COVID-19 Syndrome Patients

Retrieved on: 
星期一, 二月 19, 2024
Group 1, Coronavirus, AAAAI, Research, SARS-CoV-2, Doctor of Philosophy, Multimedia, Inflammation, Nonsteroidal anti-inflammatory drug, Enterocyte, Asthma, ELISA, Radical, Arthralgia, Group 2, COVID-19, CRP, COVID, Patient, Journal, Rehabilitation, Plasma, Ageing, Rebamipide, American Academy, Pharmaceutical industry

MILWAUKEE, Feb. 19, 2024 /PRNewswire-PRWeb/ -- Rebamipide may be useful for rehabilitation of patients with SARS-CoV-2 post-COVID syndrome according to new research being presented at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Washington, DC, this month.

Key Points: 
  • "This study revealed higher levels of lipopolysaccharide-binding protein, and lower levels of bacterial permeability protein in patients with post COVID syndrome.
  • Rebamipide, by reducing intestinal permeability, reduces endotoxin load, lowering the level of low-grade inflammation.
  • To explore Rebamipide's usefulness for rehabilitating SARS-CoV-2 post-COVID syndrome patients, researchers examined 62 patients, aged 42-55 years with post-COVID-19 syndrome using nonsteroidal anti-inflammatory drugs for joint pain.
  • Given the effects of SARS-CoV-2 on enterocytes, the results suggest that Rebamipide may be useful for rehabilitation of patients with SARS-CoV-2 post-COVID syndrome.

Notice convening the Annual General Meeting of AB Electrolux

Retrieved on: 
星期五, 二月 16, 2024
Transfer, Group 1, Person, International assignment, ABS, Sale, Electrolux, Annual report, ATTN:, Election, Legislation, Housing, Nomination, Annual general meeting, Committee, The Annual Report, Social Security, AMF, Companies Act, Malus, Group 2, PwC, Remuneration, LTI, Motivation, Mass meeting, Group 4, Retirement, General counsel, CO2, Employment, Auditor, Editorial, Chapter Eight, Group 5, Corporate governance, Group 3, Group 7, Swedish Bar Association, Audit committee, Investor AB, Administration, Disability, Report, Annual, STI, Management

The Board of Directors proposes that the following guidelines for remuneration shall be approved by the Annual General Meeting of the Company.

Key Points: 
  • The Board of Directors proposes that the following guidelines for remuneration shall be approved by the Annual General Meeting of the Company.
  • The principles shall be applied to employment and consultancy agreements entered into after the 2024 Annual General Meeting, and to changes made to existing agreements thereafter.
  • The proposal to the 2024 Annual General Meeting for resolution on guidelines for remuneration corresponds, in all material aspects, with the guidelines adopted by the 2020 Annual General Meeting.
  • The resolution of the Annual General Meeting to implement the Share Program 2024 according to a) above requires that more than half of the votes cast at the Annual General Meeting are in favor of the proposal.

Notice convening the Annual General Meeting of AB Electrolux

Retrieved on: 
星期五, 二月 16, 2024
Transfer, Group 1, Person, International assignment, ABS, Sale, Electrolux, Annual report, ATTN:, Election, Legislation, Housing, Nomination, Annual general meeting, Committee, The Annual Report, Social Security, AMF, Companies Act, Malus, Group 2, PwC, Remuneration, LTI, Motivation, Mass meeting, Group 4, Retirement, General counsel, CO2, Employment, Auditor, Editorial, Chapter Eight, Group 5, Corporate governance, Group 3, Group 7, Swedish Bar Association, Audit committee, Investor AB, Administration, Disability, Report, Annual, STI, Management

The Board of Directors proposes that the following guidelines for remuneration shall be approved by the Annual General Meeting of the Company.

Key Points: 
  • The Board of Directors proposes that the following guidelines for remuneration shall be approved by the Annual General Meeting of the Company.
  • The principles shall be applied to employment and consultancy agreements entered into after the 2024 Annual General Meeting, and to changes made to existing agreements thereafter.
  • The proposal to the 2024 Annual General Meeting for resolution on guidelines for remuneration corresponds, in all material aspects, with the guidelines adopted by the 2020 Annual General Meeting.
  • The resolution of the Annual General Meeting to implement the Share Program 2024 according to a) above requires that more than half of the votes cast at the Annual General Meeting are in favor of the proposal.

FDA Approves First Medication to Treat Severe Frostbite

Retrieved on: 
星期三, 二月 14, 2024
Human services, Group 1, Blood pressure, Division, Research, Aspirin, Headache, The, Frostbite, Cosmetics, Multimedia, Group 3, Flushing, Blood, Physician, FDA, Dietary supplement, Food, Dizziness, Skin, Nausea, Finger, Cardiology, Vomiting, Standard of care, Vaccine, Risk, Animal, Iloprost, Amputation, Safety, Heated tobacco product, Group 2, Nephrology, Public, Patient, Palpitations, Orthostatic hypertension, Hypotension, Priority review

SILVER SPRING, Md., Feb. 14, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Aurlumyn (iloprost) injection to treat severe frostbite in adults to reduce the risk of finger or toe amputation.

Key Points: 
  • SILVER SPRING, Md., Feb. 14, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Aurlumyn (iloprost) injection to treat severe frostbite in adults to reduce the risk of finger or toe amputation.
  • Frostbite can occur in several stages, ranging from mild frostbite that does not require medical intervention and does not cause permanent skin damage, to severe frostbite when both the skin and underlying tissue are frozen and blood flow is stopped, sometimes requiring amputation.
  • Iloprost's efficacy in treating severe frostbite was primarily established in an open-label, controlled trial that randomized 47 adults with severe frostbite, who all received aspirin by vein and standard of care, into one of three treatment groups.
  • The two other groups received other medications that are unapproved for frostbite, given with iloprost (Group 2) or without iloprost (Group 3).